EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC0

Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes

Harini Ganeshan iD, Jun Huang, Maria Belmonte iD, Arnel Belmonte, Sandra Inoue, Rachel Velasco, Santina Maiolatesi, Keith Limbach, Noelle Patterson, Marvin J Sklar, Lorraine Soisson, Judith E Epstein und 6 weitere

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0318098 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2025. Verfasst von Harini Ganeshan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Naval Medical Research Command, Silver Spring, Maryland, United States of America. Hauptthemen laut MEDLINE: Adenoviruses, Simian, Antigens, Protozoan, Epitopes, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: United States Agency for International Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A three-antigen DNA-prime/chimpanzee adenovirus 63 (ChAd63) boost vaccine containing pre-erythrocytic Plasmodium falciparum (Pf) circumsporozoite protein (CSP), Pf apical membrane antigen-1 (AMA1) and malaria multiple epitopes (ME) fused to Pf thrombospondin-related adhesion protein (ME-TRAP) elicited higher vaccine efficacy (VE) in an open label, randomized Phase 1 trial against controlled human malaria infection (CHMI) than the two-antigen vaccine DNA/Human Adenovirus 5 (HuAd5) containing CSP and AMA1. The objective of this follow-up study was to determine whether responses to CSP, AMA1 or TRAP MHC Class I-restricted epitopes were associated with VE. Methodology Protected (n = 6) and non-protected participants (n = 26) were screened in FluoroSpot interferon gamma (IFN-γ) and Granzyme B (GzB) assays using antigen-specific 15mer peptide subpools spanning CSP (n = 9 subpools), AMA1 (n = 12 subpools), and TRAP (n = 11 subpools). Individual antigen-specific 15mers in the subpools with strong responses were then deconvoluted, evaluated for activities, and MHC Class I-restricted epitopes within the active 15mers were predicted using NetMHCpan algorithms. The predicted epitopes were synthesized and evaluated in the FluoroSpot IFN-γ and GzB assays.

Results

Protected and some non-protected participants had similar responses to individual antigen-specific peptide subpools, which did not distinguish only protected participants. However, deconvoluted antigen-specific positive subpools with high magnitudes of responses revealed individual 15mer peptides containing specific and/or predicted MHC Class I (HLA) epitopes. Responses to epitopes were either IFN-γ-only, IFN-γ and GzB, or GzB-only. Due to limitation of cells, most of the analysis concentrated on the identification of protection associated AMA1 epitopes, since most of the predominant pool specific responses were generated against AMA1 15mer subpools. Furthermore, we previously identified protection associated HLA class I-restricted epitopes in a previous gene-based vaccine trial. Seven predicted minimal epitopes in AMA1 were synthesized and upon testing, five recalled responses from protected participants confirming their possible contribution and association with protection, and two recalled responses from non-protected participants. Two protection-associated epitopes were promiscuous and may have also contributed to protection by recognition of different HLA alleles. In addition, strongly positive antigen-specific 15mers identified within active antigen-specific subpools contained 39 predicted but not tested epitopes were identified in CSP, AMA1 and TRAP. Finally, some non-protected individuals recognized HLA-matched protection-associated minimal epitopes and we discuss possible reasons. Other factors such as HLA allele fine specificity or interaction between other HLA alleles in same individual may also influence protective efficacy.

Conclusions

This integrated approach using immunoassays and bioinformatics identified and confirmed AMA1-MHC Class I-restricted epitopes and a list of predicted additional epitopes which could be evaluated in future studies to assess possible association with protection against CHMI in the Phase 1 trial participants. The results suggest that identification of protection-associated epitopes within malaria antigens is feasible and can help design potent next generation multi-antigen, multi-epitope malaria vaccines for a genetically diverse population and to develop robust assays to measure protective cellular immunity against pre-erythrocytic stages of malaria. This approach can be used to develop vaccines for other novel emerging infectious disease pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenoviruses, SimianAntigens, ProtozoanEpitopesHistocompatibility Antigens Class IMalaria VaccinesMalaria, FalciparumVaccines, DNAAdolescentAdultAnimalsFemaleHumansMaleYoung AdultMembrane ProteinsPlasmodium falciparumProtozoan Proteins

Substanzen

Antigens, Protozoanapical membrane antigen I, Plasmodiumcircumsporozoite protein, ProtozoanEpitopesHistocompatibility Antigens Class IMalaria VaccinesMembrane Proteinsthrombospondin-related adhesive protein, protozoanVaccines, DNAProtozoan Proteins

Autor:innen und Institutionen

  • Naval Medical Research Command, Silver Spring, Maryland, United States of America.
  • The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • General Dynamics Information Technology, Falls Church, Virginia, United States of America.
  • United States Agency for International Development (USAID), Washington, DC, United States of America.
  • Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • La Jolla Institute of Allergy and Immunology, La Jolla, California, United States of America.

ORCID-Profile: Harini Ganeshan, Maria Belmonte, Martha Sedegah

Förderung

  • United States Agency for International Development

Zitieren

APA

Ganeshan, H., Huang, J., Belmonte, M., Belmonte, A., Inoue, S., Velasco, R., Maiolatesi, S., Limbach, K., Patterson, N., Sklar, M. J., Soisson, L., Epstein, J. E., Edgel, K. A., Peters, B., Hollingdale, M. R., Villasante, E., Duplessis, C. A., & Sedegah, M. (2025). Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes. PLOS ONE. https://doi.org/10.1371/journal.pone.0318098

Vancouver

Ganeshan H, Huang J, Belmonte M, Belmonte A, Inoue S, Velasco R, et al. Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes. PLOS ONE. 2025. doi:10.1371/journal.pone.0318098

BibTeX
@article{Ganeshan2025,
  author = {Ganeshan, Harini and Huang, Jun and Belmonte, Maria and Belmonte, Arnel and Inoue, Sandra and Velasco, Rachel and Maiolatesi, Santina and Limbach, Keith and Patterson, Noelle and Sklar, Marvin J and Soisson, Lorraine and Epstein, Judith E and Edgel, Kimberly A and Peters, Bjoern and Hollingdale, Michael R and Villasante, Eileen and Duplessis, Christopher A and Sedegah, Martha},
  title = {Human responses to the DNA prime/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0318098}
}
Kostenlos starten →